This study is designed to further strengthen the clinical application evidence of BaidiZiyin Pill and ShenqiYifei Pill in the treatment of tuberculosis. To be included in the initial treatment of pulmonary tuberculosis patients, on the basis of standardized Western medicine treatment, BaidiZiyin Pills and ShenqiYifei Pills will be used to evaluate the clinical efficacy and safety of their products.
1. Evaluate the improvement of symptoms in the adjuvant treatment of newly treated pulmonary tuberculosis with BaidiZiyin Pill and ShenqiYifei Pill.
2. Explore the sputum negative conversion time and sputum negative conversion rate of BaidiZiyin Pill and ShenqiYifei Pill as adjunctive treatments for newly treated pulmonary tuberculosis.
3. Explore the protective effects of BaidiZiyin Pill and ShenqiYifei Pill on adverse reactions caused by chemotherapy.
Phase:
PHASE4
Details
Lead Sponsor:
Beijing Chest Hospital
Collaborators:
Anhui Chest Hospital Chengdu Public Health Clinical Medical Center Chongqing Public Health Guangzhou Chest Hospital. Hebei Chest Hospital Heilongjiang Provincial Institute of Infectious Disease Prevention and Control Lanzhou Pulmonary Hospital Shenyang Tenth People's Hospital Suzhou Fifth Hospital The First Affiliated Hospital with Nanjing Medical University Third People's Court of Shenzhen Wuhan tuberculosis Hospital